Related references
Note: Only part of the references are listed.Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Paul G. Richardson et al.
BLOOD (2010)
Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
Maria-Victoria Mateos et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline
Paul G. Richardson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
Cyrille Hulin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Heparan sulfate proteoglycans, Fc receptors, and DC suppression
Eddy Roosnek et al.
BLOOD (2008)
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
Antonio Palumbo et al.
BLOOD (2008)
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature
Andreas A. Argyriou et al.
BLOOD (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: Consensus statement of the IMF Nurse Leadership Board
Joseph D. Tariman et al.
CLINICAL JOURNAL OF ONCOLOGY NURSING (2008)
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
Thierry Facon et al.
LANCET (2007)
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma:: A report from the GIMEMA -: Italian multiple myeloma network
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma
Antonio Palumbo et al.
BLOOD (2007)
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature
Ashraf Badros et al.
CANCER (2007)
Development of neuropathy in patients with myeloma treated with thalidomide: Patterns of occurrence and the role of electrophysiologic monitoring
Linda Mileshkin et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled-trial
A Palumbo et al.
LANCET (2006)